Sequential, a leader in genomic testing from non-invasive human clinical samples, has closed its first equity round, securing $3.5 million.

The round was co-led by Sparkfood and Corundum Systems Biology (CSB), with participation from Dermazone Holdings, SOSV, Scrum Ventures, an ex-General Partner at Index Ventures, alongside continued support from Innovate UK. With this raise, Sequential has secured a total of $7.5m in dilutive and non-dilutive funding to date.

Sequential advances innovation in skin health by quantifying how ingredients and consumer, biotech, and pharmaceutical products alter microbial and host biomarkers, using its proprietary non-invasive testing platform.

The company has built one of the most comprehensive clinical datasets in the industry, comprising over 50,000 samples, 4,000+ ingredients, and 10,000+ participants worldwide.